NewLimit Blog

Home
Archive
About
September-October 2023 Progress Update
Expanding the palette & compounding returns
 • 
Jacob C. Kimmel
New
Top
July-August 2023 Progress Update
Recursive record setting
 • 
Jacob C. Kimmel
May-June 2023 Progress Update
Pure yields
 • 
Jacob C. Kimmel
NewLimit secures $40 million in venture funding from Dimension Capital, Founders Fund, Kleiner Perkins and other investors
NewLimit works across cell biology, genomics, machine learning, and cellular reprogramming to treat diseases and reverse aging
 • 
Brian Armstrong
, 
Blake Byers
, 
Greg Johnson
, and 
Jacob C. Kimmel
April 2023 Progress Update
Overcoming a primary challenge
 • 
Jacob C. Kimmel
March 2023 Progress Update - Live Event!
This time with live video
 • 
Jacob C. Kimmel
 and 
Brian Armstrong
February 2023 Progress Update
Screening at scale
 • 
Jacob C. Kimmel
January 2023 Update
Bridging Atoms and Bits
 • 
Greg Johnson
NewLimit Blog
NewLimit Blog
Progress reports from our work to develop epigenetic reprogramming medicines for aging

NewLimit Blog

AboutArchiveSitemap
© 2023 NewLimit Inc.
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing